CN112689507B - 具有无支链接头的氨基酸化合物及其使用方法 - Google Patents

具有无支链接头的氨基酸化合物及其使用方法 Download PDF

Info

Publication number
CN112689507B
CN112689507B CN201980050125.6A CN201980050125A CN112689507B CN 112689507 B CN112689507 B CN 112689507B CN 201980050125 A CN201980050125 A CN 201980050125A CN 112689507 B CN112689507 B CN 112689507B
Authority
CN
China
Prior art keywords
tetrahydro
naphthyridin
compound
nonanoic acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980050125.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112689507A (zh
Inventor
K·莱夫特里斯
M·莱利
D·芬克尔斯坦
N·库珀
C·贝利
J·查
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of CN112689507A publication Critical patent/CN112689507A/zh
Application granted granted Critical
Publication of CN112689507B publication Critical patent/CN112689507B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
CN201980050125.6A 2018-06-27 2019-06-27 具有无支链接头的氨基酸化合物及其使用方法 Active CN112689507B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690939P 2018-06-27 2018-06-27
US62/690,939 2018-06-27
PCT/US2019/039624 WO2020006315A1 (en) 2018-06-27 2019-06-27 Amino acid compounds with unbranched linkers and methods of use

Publications (2)

Publication Number Publication Date
CN112689507A CN112689507A (zh) 2021-04-20
CN112689507B true CN112689507B (zh) 2024-07-30

Family

ID=68987528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050125.6A Active CN112689507B (zh) 2018-06-27 2019-06-27 具有无支链接头的氨基酸化合物及其使用方法

Country Status (24)

Country Link
US (3) US11396506B2 (enExample)
EP (1) EP3813818A4 (enExample)
JP (2) JP7425757B2 (enExample)
KR (1) KR20210043561A (enExample)
CN (1) CN112689507B (enExample)
AU (1) AU2019295769B2 (enExample)
BR (1) BR112020026278A2 (enExample)
CA (1) CA3104682A1 (enExample)
CL (1) CL2020003382A1 (enExample)
CR (1) CR20210041A (enExample)
CU (1) CU24693B1 (enExample)
DO (1) DOP2020000255A (enExample)
EA (1) EA202190134A1 (enExample)
EC (1) ECSP21005655A (enExample)
IL (2) IL279717B2 (enExample)
JO (1) JOP20200330A1 (enExample)
MX (1) MX2020014086A (enExample)
PE (1) PE20210137A1 (enExample)
PH (1) PH12020552260A1 (enExample)
SA (1) SA520420897B1 (enExample)
SG (1) SG11202013027RA (enExample)
TW (1) TWI841573B (enExample)
WO (1) WO2020006315A1 (enExample)
ZA (1) ZA202100211B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
CA3045491A1 (en) 2016-12-29 2018-07-19 Indalo Therapeutics, Inc. Integrin antagonists
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
TWI776067B (zh) 2018-06-29 2022-09-01 美商維托平面玻璃有限責任公司 可燒除保護性塗層
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
EP4076454A1 (en) * 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
IL293895A (en) * 2019-12-20 2022-08-01 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
GB202010626D0 (en) * 2020-07-10 2020-08-26 Univ Nottingham Compound
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284944A (zh) * 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
WO2008093064A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS
WO2018049068A1 (en) * 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
WO2018119087A1 (en) * 2016-12-23 2018-06-28 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2018160522A1 (en) * 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN104817604B (zh) 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
JP2018514568A (ja) * 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
KR20190026001A (ko) 2016-07-05 2019-03-12 더 락커펠러 유니버시티 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
CN110167934B (zh) * 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
CN115151566A (zh) 2019-11-15 2022-10-04 普利安特治疗公司 用于活化整合素的组合物和方法
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20230028658A1 (en) 2021-04-30 2023-01-26 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
JP2024539645A (ja) 2021-10-14 2024-10-29 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤及び他の薬剤と組み合わせたその使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284944A (zh) * 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
WO2008093064A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS
WO2018049068A1 (en) * 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
WO2018119087A1 (en) * 2016-12-23 2018-06-28 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
WO2018160522A1 (en) * 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin

Also Published As

Publication number Publication date
CN112689507A (zh) 2021-04-20
AU2019295769A1 (en) 2021-02-11
IL279717A (en) 2021-03-01
SG11202013027RA (en) 2021-01-28
PH12020552260A1 (en) 2021-08-16
CL2020003382A1 (es) 2021-05-14
CU24693B1 (es) 2024-02-07
JP7425757B2 (ja) 2024-01-31
EP3813818A4 (en) 2023-01-11
DOP2020000255A (es) 2021-05-16
IL279717B2 (en) 2024-05-01
AU2019295769B2 (en) 2024-05-23
US20200123151A1 (en) 2020-04-23
US11396506B2 (en) 2022-07-26
US11858931B2 (en) 2024-01-02
EP3813818A1 (en) 2021-05-05
WO2020006315A1 (en) 2020-01-02
CU20210001A7 (es) 2021-08-06
KR20210043561A (ko) 2021-04-21
US20220289743A1 (en) 2022-09-15
TW202010492A (zh) 2020-03-16
SA520420897B1 (ar) 2024-03-30
US20240294520A1 (en) 2024-09-05
BR112020026278A2 (pt) 2021-04-06
EA202190134A1 (ru) 2021-03-26
JOP20200330A1 (ar) 2020-12-20
CA3104682A1 (en) 2020-01-02
ECSP21005655A (es) 2021-02-26
TWI841573B (zh) 2024-05-11
JP2021529755A (ja) 2021-11-04
MX2020014086A (es) 2021-04-13
IL279717B1 (en) 2024-01-01
CR20210041A (es) 2021-03-02
IL308960A (en) 2024-01-01
PE20210137A1 (es) 2021-01-21
JP2024055873A (ja) 2024-04-18
ZA202100211B (en) 2025-05-28

Similar Documents

Publication Publication Date Title
US11858931B2 (en) Amino acid compounds with unbranched linkers and methods of use
US11952376B2 (en) Substituted amino acids as integrin inhibitors
JP7379467B2 (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
JP2024009916A (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
JP7834830B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
CA2481482C (en) Tropane derivatives as ccr5 modulators
EA033626B1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-а]ПИРИДИНКАРБОКСАМИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИХ
JP6749422B2 (ja) プロテインキナーゼ阻害剤である新規な２，３，５−置換チオフェン化合物
TW202329973A (zh) 整合素抑制劑及其與其他藥劑併用之用途
CA3154136C (en) MLL-1 INHIBITORS AND ANTICANCER AGENTS
HK40049583A (en) Amino acid compounds with unbranched linkers and methods of use
BR122023025996A2 (pt) Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção
WO2026047577A1 (en) Hydroquinazoline derivatives and treatment of a disease or disorder using the same
EA050655B1 (ru) Замещенные бициклические соединения, пригодные для применения в качестве ингибиторов tlr9
EA045845B1 (ru) Противовирусные средства для лечения и профилактики вич-инфекции

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049583

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant